Heron Therapeutics (NASDAQ: HRTX) reported Q1 EPS of ($0.63), $0.15 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $22.4 million versus the consensus estimate of $22.61 million.

GUIDANCE:

Heron Therapeutics sees FY2022 revenue of $89-93 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.